INTELLIGENT_HEALTH_LIMITE - Accounts


Company registration number 05760628 (England and Wales)
INTELLIGENT HEALTH LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023
PAGES FOR FILING WITH REGISTRAR
INTELLIGENT HEALTH LIMITED
CONTENTS
Page
Directors' report
1
Balance sheet
2 - 3
Notes to the financial statements
4 - 9
INTELLIGENT HEALTH LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 30 JUNE 2023
- 1 -

The directors present their annual report and financial statements for the year ended 30 June 2023.

Principal activities
The principal activity of the company continued to be that of the development of solutions for the health sector relating to increasing physical activity through the use of technology.
Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Dr C W H Bird
G T Sewell
I R H Simpkin
(Resigned 1 December 2022)
K Knight
D J Walters
Mr K McDonnell
Mr S J Hartwell
(Appointed 7 December 2023)
Small companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board
Dr C W H Bird
Director
18 January 2024
INTELLIGENT HEALTH LIMITED
BALANCE SHEET
AS AT 30 JUNE 2023
30 June 2023
- 2 -
2023
2022
Notes
Fixed assets
Intangible assets
3
533,073
382,765
Tangible assets
4
14,901
17,472
547,974
400,237
Current assets
Stocks
86,138
90,447
Debtors
5
64,586
244,165
Cash at bank and in hand
288,685
737,232
439,409
1,071,844
Creditors: amounts falling due within one year
6
(1,118,275)
(1,316,521)
Net current liabilities
(678,866)
(244,677)
Total assets less current liabilities
(130,892)
155,560
Creditors: amounts falling due after more than one year
7
(21,549)
(37,995)
Provisions for liabilities
18,000
18,000
Net (liabilities)/assets
(134,441)
135,565
Capital and reserves
Called up share capital
8
2,274
2,274
Share premium account
1,499,500
1,499,500
Profit and loss reserves
(1,636,215)
(1,366,209)
Total equity
(134,441)
135,565

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 June 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

INTELLIGENT HEALTH LIMITED
BALANCE SHEET (CONTINUED)
AS AT 30 JUNE 2023
30 June 2023
- 3 -
The financial statements were approved by the board of directors and authorised for issue on 18 January 2024 and are signed on its behalf by:
Dr C W H Bird
Director
Company Registration No. 05760628
INTELLIGENT HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023
- 4 -
1
Accounting policies
Company information

Intelligent Health Limited is a private company limited by shares incorporated in England and Wales. The registered office is Reading Enterprise Centre, Reading University, Earley Gate, Reading, Berkshire, RG6 6BU.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest .

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

These financial statements are prepared on the going concern basis. The directors have a reasonable expectation that the company will continue in operational existence for the foreseeable future. However, the directors are aware of certain material uncertainties which may cause doubt on the company's ability to continue as a going concern.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

1.4
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.5
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Beat the Street mobile application; to write off over 5 years straight line, post launch
Beat the Street CMS and database; My activity tracker
Written off over 5 years straight line on cost
INTELLIGENT HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2023
1
Accounting policies
(Continued)
- 5 -
1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery
Straight line on cost over 3 years
Fixtures, fittings & equipment
25% straight line on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

1.9
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

INTELLIGENT HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2023
1
Accounting policies
(Continued)
- 6 -
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.11
Compound instruments

The component parts of compound instruments issued by the company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. This amount is recorded as a liability on an amortised cost basis using the effective interest method until extinguished upon conversion or at the instrument's maturity date. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognised and included in equity net of income tax effects and is not subsequently remeasured.

1.12
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.13
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

INTELLIGENT HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2023
1
Accounting policies
(Continued)
- 7 -
1.14
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

1.15
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.16
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2023
2022
Number
Number
Total
38
38
3
Intangible fixed assets
Beat the Street mobile application; to write off over 5 years straight line, post launch
Beat the Street CMS and database; My activity tracker
Total
Cost
At 1 July 2022
341,337
777,063
1,118,400
Additions - internally developed
311,160
-
0
311,160
At 30 June 2023
652,497
777,063
1,429,560
Amortisation and impairment
At 1 July 2022
44,718
690,917
735,635
Amortisation charged for the year
122,707
38,145
160,852
At 30 June 2023
167,425
729,062
896,487
Carrying amount
At 30 June 2023
485,072
48,001
533,073
At 30 June 2022
296,619
86,146
382,765
INTELLIGENT HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2023
- 8 -
4
Tangible fixed assets
Plant and machinery
Fixtures, fittings & equipment
Total
Cost
At 1 July 2022
841,893
70,258
912,151
Additions
-
0
7,063
7,063
At 30 June 2023
841,893
77,321
919,214
Depreciation and impairment
At 1 July 2022
839,537
55,142
894,679
Depreciation charged in the year
2,356
7,278
9,634
At 30 June 2023
841,893
62,420
904,313
Carrying amount
At 30 June 2023
-
0
14,901
14,901
At 30 June 2022
2,356
15,116
17,472
5
Debtors
2023
2022
Amounts falling due within one year:
Trade debtors
41,399
223,816
Other debtors
23,187
20,349
64,586
244,165
6
Creditors: amounts falling due within one year
2023
2022
Notes
Convertible loans
21,875
87,500
Other borrowings
17,583
48,333
Trade creditors
105,705
107,218
Taxation and social security
50,233
92,432
Deferred income
728,996
755,666
Other creditors
130,132
44,913
Accruals
63,751
180,459
1,118,275
1,316,521
INTELLIGENT HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2023
- 9 -
7
Creditors: amounts falling due after more than one year
2023
2022
Other creditors
21,549
37,995
8
Called up share capital
2023
2022
2023
2022
Ordinary share capital
Number
Number
Issued and fully paid
Ordinary of 1p each
114,700
114,700
1,147
1,147
A ordinary shares of 1p each
112,719
112,719
1,127
1,127
227,419
227,419
2,274
2,274
2023-06-302022-07-01false18 January 2024CCH SoftwareCCH Accounts Production 2023.100No description of principal activityDr C W H BirdG T SewellI R H SimpkinK KnightD J WaltersMr K McDonnellMr S J HartwellMr S J Hartwell057606282022-07-012023-06-3005760628bus:Director12022-07-012023-06-3005760628bus:Director22022-07-012023-06-3005760628bus:Director32022-07-012023-06-3005760628bus:Director42022-07-012023-06-3005760628bus:Director52022-07-012023-06-3005760628bus:Director62022-07-012023-06-3005760628bus:CompanySecretaryDirector12022-07-012023-06-3005760628bus:Director72022-07-012023-06-3005760628bus:CompanySecretary12022-07-012023-06-30057606282023-06-30057606282022-06-3005760628core:ComputerSoftware2023-06-3005760628core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-06-3005760628core:ComputerSoftware2022-06-3005760628core:DevelopmentCostsCapitalisedDevelopmentExpenditure2022-06-3005760628core:PlantMachinery2023-06-3005760628core:FurnitureFittings2023-06-3005760628core:PlantMachinery2022-06-3005760628core:FurnitureFittings2022-06-3005760628core:CurrentFinancialInstrumentscore:WithinOneYear2023-06-3005760628core:CurrentFinancialInstrumentscore:WithinOneYear2022-06-3005760628core:Non-currentFinancialInstrumentscore:AfterOneYear2023-06-3005760628core:Non-currentFinancialInstrumentscore:AfterOneYear2022-06-3005760628core:CurrentFinancialInstruments2023-06-3005760628core:CurrentFinancialInstruments2022-06-3005760628core:ShareCapital2023-06-3005760628core:ShareCapital2022-06-3005760628core:SharePremium2023-06-3005760628core:SharePremium2022-06-3005760628core:RetainedEarningsAccumulatedLosses2023-06-3005760628core:RetainedEarningsAccumulatedLosses2022-06-3005760628core:ShareCapitalOrdinaryShares2023-06-3005760628core:ShareCapitalOrdinaryShares2022-06-3005760628core:IntangibleAssetsOtherThanGoodwill2022-07-012023-06-3005760628core:DevelopmentCostsCapitalisedDevelopmentExpenditure2022-07-012023-06-3005760628core:PlantMachinery2022-07-012023-06-3005760628core:FurnitureFittings2022-07-012023-06-30057606282021-07-012022-06-3005760628core:ComputerSoftware2022-06-3005760628core:DevelopmentCostsCapitalisedDevelopmentExpenditure2022-06-30057606282022-06-3005760628core:ComputerSoftwarecore:InternallyGeneratedIntangibleAssets2022-07-012023-06-3005760628core:DevelopmentCostsCapitalisedDevelopmentExpenditurecore:InternallyGeneratedIntangibleAssets2022-07-012023-06-3005760628core:InternallyGeneratedIntangibleAssets2022-07-012023-06-3005760628core:ComputerSoftware2022-07-012023-06-3005760628core:PlantMachinery2022-06-3005760628core:FurnitureFittings2022-06-3005760628core:WithinOneYear2023-06-3005760628core:WithinOneYear2022-06-3005760628core:Non-currentFinancialInstruments2023-06-3005760628core:Non-currentFinancialInstruments2022-06-3005760628bus:PrivateLimitedCompanyLtd2022-07-012023-06-3005760628bus:SmallCompaniesRegimeForAccounts2022-07-012023-06-3005760628bus:FRS1022022-07-012023-06-3005760628bus:AuditExemptWithAccountantsReport2022-07-012023-06-3005760628bus:FullAccounts2022-07-012023-06-30xbrli:purexbrli:sharesiso4217:GBP